Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by CancerSlayeron Mar 14, 2023 4:17pm
252 Views
Post# 35338308

RE:RE:RE:Opportunity to add more

RE:RE:RE:Opportunity to add more

Eoganacht wrote: My guess, (and that of many others), is they received some sort of assurances from the FDA and/or a big pharma. 

Last September Dr. Mandel bought 100,000 shares for $25,000 and the Dumoulin-White/Hachey family bought 2,711,000 more shares for $677,750. all with their own money. I think this is the first time Dr. Mandel bought shares.

One might speculate that the granting of 25 cent options in November is one last insider trip to the trough while there's still time:

John Anderson - 1,2500,000
Randall Bruder - 1,000,000
Roger Dumoilin-White - 1,500,000
Kristina Hachey - 1,500,000
Arkady Mandel - 1,500,000.

 

Per that recent BT article, Dr. Mandel seemed very confident in his tone & timelines.  The reported plans to add up to an additional 9 clinical trial sites in 2023 seems to be a lofty goal w/o some prior assurances made.  I understand we are at the tail end of a pandemic, but initiating & manintaining this number of sites through study completion generally requires a significant amount of time/funding/coordination (even with the assistance of a CRO).  

Dr. Mandel's 9/2022 purchase of shares is certainly a show of confidence & a strong signal that he is willing to put his mouth where his money is ; ).   All imo.

<< Previous
Bullboard Posts
Next >>